Micro-RNA-21 (miR21) expression in colorectal cancer (CRC) as a predictor for fluoropyrimidine-based adjuvant chemotherapy

被引：0
|
作者：
Lin, Albert Y.
Kouzminova, Natalia B.
Pollack, Jonathan
Nuovo, Gerard
机构：
[1] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[3] OSU Comprehens Canc Ctr, Powell, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.408
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
408
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer
    Aschele, C
    Lonardi, S
    Monfardini, S
    CANCER TREATMENT REVIEWS, 2002, 28 (01) : 27 - 47
  • [2] MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival
    Mima, Kosuke
    Nishihara, Reiko
    Yang, Juhong
    Dou, Ruoxu
    Masugi, Yohei
    Shi, Yan
    da Silva, Annacarolina
    Cao, Yin
    Song, Mingyang
    Nowak, Jonathan
    Gu, Mancang
    Li, Wanwan
    Morikawa, Teppei
    Zhang, Xuehong
    Wu, Kana
    Baba, Hideo
    Giovannucci, Edward L.
    Meyerhardt, Jeffrey A.
    Chan, Andrew T.
    Fuchs, Charles S.
    Qian, Zhi Rong
    Ogino, Shuji
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3841 - 3848
  • [3] MicroRNA MIR21 and T Cells in Colorectal Cancer
    Mima, Kosuke
    Nishihara, Reiko
    Nowak, Jonathan A.
    Kim, Sun A.
    Song, Mingyang
    Inamura, Kentaro
    Sukawa, Yasutaka
    Masuda, Atsuhiro
    Yang, Juhong
    Dou, Ruoxu
    Nosho, Katsuhiko
    Baba, Hideo
    Giovannucci, Edward L.
    Bowden, Michaela
    Loda, Massimo
    Giannakis, Marios
    Bass, Adam J.
    Dranoff, Glenn
    Freeman, Gordon J.
    Chan, Andrew T.
    Fuchs, Charles S.
    Qian, Zhi Rong
    Ogino, Shuji
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01) : 33 - 40
  • [4] MicroRNA MIR21, T cells, and PTGS2 expression in Colorectal Cancer
    Mima, K.
    Nishihara, R.
    Qian, Z. R.
    Baba, H.
    Ogino, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy
    Cohen, V
    Panet-Raymond, V
    Sabbaghian, N
    Morin, I
    Batist, G
    Rozen, R
    CLINICAL CANCER RESEARCH, 2003, 9 (05) : 1611 - 1615
  • [6] Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer
    Huang, Wen-Kuan
    Ho, Wei-Pang
    Hsu, Hung-Chih
    Chang, Shu-Hao
    Chen, Dong-Yi
    Chou, Wen-Chi
    Chang, Pei-Hung
    Chen, Jen-Shi
    Yang, Tsai-Sheng
    See, Lai-Chu
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [7] Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer
    Hurwitz, H
    Kabbinavar, F
    ONCOLOGY, 2005, 69 : 17 - 24
  • [8] Optimal cycles of fluoropyrimidine-based adjuvant chemotherapy for patients with resectable gastric cancer.
    Liu, Yunpeng
    Qu, Xiujuan
    Qu, Jinglei
    Zhang, Jingdong
    Liu, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer
    Stanisavljevic, Luka
    Myklebust, Mette P.
    Leh, Sabine
    Dahl, Olav
    ACTA ONCOLOGICA, 2016, 55 (12) : 1425 - 1433
  • [10] Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy
    Kichenadasse, Ganessan
    Miners, John O.
    Mangoni, Arduino A.
    Karapetis, Christos S.
    Hopkins, Ashley M.
    Sorich, Michael J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (09): : 1037 - +
12345